-
公开(公告)号:US20190247383A1
公开(公告)日:2019-08-15
申请号:US16195966
申请日:2018-11-20
发明人: Hesheng Zhang
IPC分类号: A61K31/454 , C07D401/14 , A61K31/445 , C07D401/04
CPC分类号: A61K31/454 , A61K31/445 , C07D401/04 , C07D401/14 , Y02A50/411
摘要: This invention is directed to derivatives of piperidine-2,6-dione, or their organic or inorganic salts thereof, a methods of synthesis of these derivatives, and their application as active pharmaceutical ingredient as inhibitors of TNFα releasing in cells, the derivative of piperidine-2,6-dione being of the general formula (I): wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent independently and at each occurrence H or C1-4 alkyl; R5 represents CHR6NR7R, CHR6NR9C(O)CHR10NR7R8, a heterocycle W or CHR6NR9C(O)W; R6, R9, R10 represent independently and at each occurrence H, or C1-4 alkyl; R7 and R8 represent independently and at each occurrence H, C1-4 alkyl, or R7 and R8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene, or 1,6-hexylene; W represents four-membered, five-membered, six-membered, seven-membered, or eight-membered saturated or unsaturated heterocycle.
-
公开(公告)号:US20190240351A1
公开(公告)日:2019-08-08
申请号:US15789138
申请日:2017-10-20
申请人: ModernaTX, Inc.
发明人: Stephane BANCEL , Tirtha CHAKRABORTY , Antonin DE FOUGEROLLES , Sayda M. ELBASHIR , Jeff Lynn ELLSWORTH , Kenechi EJEBE , Justin GUILD , Matthias JOHN , Paul HATALA , Atanu ROY , Jason P. SCHRUM , Susan WHORISKEY , Kristy M. WOOD
IPC分类号: A61K48/00 , C07K14/535 , C07K14/47 , C07K14/515 , A61K9/127 , C12N9/64 , A61K31/7115 , A61K47/54 , A61K9/51 , A61K9/14 , C12N15/87 , C12N15/85 , C12N9/00 , C07K14/705 , C07K14/62 , C07K14/505 , C07K14/485 , C07K14/435 , A61K38/45 , A61K38/17 , A61K38/48 , C07K14/525 , C07K14/56 , C07K16/00 , C12P21/00 , A61K38/18 , A61K38/19 , A61K38/21 , C12P13/04 , C12N15/52 , C12N15/11 , C12N9/88 , C12N9/42 , C12N9/24 , C12N9/16 , C12N9/10 , C07K14/005
CPC分类号: A61K48/0066 , A61K9/1271 , A61K9/145 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/177 , A61K38/1816 , A61K38/1891 , A61K38/191 , A61K38/193 , A61K38/212 , A61K38/45 , A61K38/4846 , A61K47/543 , A61K48/0033 , A61K48/005 , A61K48/0075 , C07H21/02 , C07K14/005 , C07K14/435 , C07K14/43595 , C07K14/47 , C07K14/4705 , C07K14/4713 , C07K14/4723 , C07K14/4746 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/5418 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/705 , C07K14/745 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/40 , C12N9/0069 , C12N9/0091 , C12N9/1051 , C12N9/1241 , C12N9/16 , C12N9/2402 , C12N9/2445 , C12N9/6435 , C12N9/6437 , C12N9/644 , C12N9/6443 , C12N9/6451 , C12N9/88 , C12N9/93 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00 , C12P21/005 , C12Y113/12007 , C12Y116/03001 , C12Y207/07012 , C12Y304/21007 , C12Y304/21022 , C12Y304/21027 , C12Y403/02001 , C12Y603/02019 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , Y02A50/463 , Y02A50/491
摘要: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
-
公开(公告)号:US20190153429A1
公开(公告)日:2019-05-23
申请号:US16021892
申请日:2018-06-28
发明人: Zefeng Wang , Rajarshi Choudhury
CPC分类号: C12N15/102 , A61K38/465 , C07K2319/85 , C12N7/00 , C12N9/16 , C12N9/22 , C12N15/86 , C12N2750/14143 , C12Q1/44 , G01N2333/08 , G01N2333/922 , Y02A50/409 , Y02A50/411 , Y02A50/414
摘要: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.
-
公开(公告)号:US20190112321A1
公开(公告)日:2019-04-18
申请号:US16088695
申请日:2017-03-30
发明人: Dumbala Srinivasa Reddy , Dhanasekaran Shanmugam , Remya Ramesh , Anurag Shukla , Meenakshi Anil Belekar
IPC分类号: C07F7/08 , C07D413/10 , A61P33/06
CPC分类号: C07F7/0816 , A61K31/695 , A61K45/06 , A61P33/06 , C07D413/10 , Y02A50/411
摘要: The present invention discloses a silicon incorporated quinoline of formula (I) wherein, X, Y, A, R1 and R2 are as described. The present invention further discloses a process for the preparation of silicon incorporated quinolines of formula I; a pharmaceutical composition comprising silicon incorporated quinolines of formula (I) or pharmaceutically acceptable salt thereof. The present invention also discloses a method for treating diseases caused by Plasmodium falciparum or other coccidian parasites using the silicon incorporated quinolines of formula I or pharmaceutically acceptable salt thereof.
-
公开(公告)号:US20190070137A1
公开(公告)日:2019-03-07
申请号:US16166272
申请日:2018-10-22
IPC分类号: A61K31/192 , A61K47/44 , A61K47/22 , A61K9/08 , A61K9/20 , A61K31/12 , A61K31/121 , A61K31/196 , A61K47/14 , A61K47/10 , A61K31/616 , A61K31/60 , A61K31/201 , A61K31/202 , A61K31/704 , A61K31/25 , A61K31/337
CPC分类号: A61K31/192 , A61K9/08 , A61K9/2013 , A61K31/12 , A61K31/121 , A61K31/196 , A61K31/201 , A61K31/202 , A61K31/25 , A61K31/337 , A61K31/60 , A61K31/616 , A61K31/704 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/44 , Y02A50/411
摘要: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
-
公开(公告)号:US20190010152A1
公开(公告)日:2019-01-10
申请号:US16032282
申请日:2018-07-11
申请人: Curis, Inc.
发明人: Xiong Cai , Changgeng Qian , Haixiao Zhai
IPC分类号: C07D471/04 , A61K31/4545 , A61K31/437
CPC分类号: C07D471/04 , A61K31/437 , A61K31/4545 , Y02A50/411
摘要: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
-
公开(公告)号:US20180360839A1
公开(公告)日:2018-12-20
申请号:US16113327
申请日:2018-08-27
申请人: vTv Therapeutics LLC
IPC分类号: A61K31/519 , C07D471/04
CPC分类号: A61K31/519 , C07D471/04 , Y02A50/411
摘要: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.
-
公开(公告)号:US20180360775A1
公开(公告)日:2018-12-20
申请号:US15780618
申请日:2016-12-02
发明人: Anandasankar RAY
IPC分类号: A61K31/121 , A61K9/00 , A61P25/28
CPC分类号: A61K31/121 , A61K9/0043 , A61K9/007 , A61K48/00 , A61P25/28 , Y02A50/411
摘要: Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas or vapor. Such inhibitors can be used as therapeutics for numerous disease conditions, such as a variety of cancers, neural degenerative diseases, neurological diseases, senescence, and infectious diseases.
-
9.
公开(公告)号:US20180355025A1
公开(公告)日:2018-12-13
申请号:US15988989
申请日:2018-05-24
CPC分类号: C07K16/00 , A61K38/00 , A61K47/65 , A61K47/6811 , A61K47/6849 , C07K5/0205 , C07K5/10 , C07K7/02 , C07K7/06 , C07K16/2878 , Y02A50/402 , Y02A50/411 , Y02A50/422 , Y02A50/471 , Y02A50/483
摘要: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
-
公开(公告)号:US20180333436A1
公开(公告)日:2018-11-22
申请号:US15755859
申请日:2016-08-29
发明人: Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC分类号: A61K35/28 , C12N5/0775
CPC分类号: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/411
摘要: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
-
-
-
-
-
-
-
-